To include your compound in the COVID-19 Resource Center, submit it here.

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors.

Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round that will

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers